Additionally, tumors with high mutational burden (TMB), virus driven cancers such as Merkel cell carcinoma (MCC), and tumor types with increased abundances of neoantigens—in the case of RCC, are highly immunogenic and known to respond to ICT in spite of PD-L1 negative status [80,98,99,100]. This evidence concerns the gene CD274 and cancer.